VIVANI MEDICAL INC (VANI)

Company Profile

Vivani Medical, Inc. develops and commercializes drug and device implants that treat patients with chronic diseases with high unmet medical need. The company is headquartered in Alameda, California and currently employs 44 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, the Company develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Its lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight individuals. Its pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight management in obese and overweight individuals. NPM-119 refers to its Type II diabetes development program. OKV-119 is an exenatide implant that is under development for metabolic diseases in cats, including for the treatment of obesity and diabetes. Its segments include Biopharm Division and Neurostimulation Division.

Company Info

VIVANI MEDICAL INC

1350 S. Loop Road

Alameda CALIFORNIA

P: 14155068462

Employees: 36

Website: https://vivani.com/